Previous close | 187.70 |
Open | 187.70 |
Bid | 186.45 |
Ask | 191.25 |
Strike | 360.00 |
Expiry date | 2022-09-16 |
Day's range | 187.70 - 187.70 |
Contract range | N/A |
Volume | |
Open interest | 8 |
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
On that note, Ocugen (NASDAQ: OCGN) stock is down by more than 65% this year as the small biotech has struggled to commercialize a coronavirus vaccine. To remedy that issue, it's licensing a coronavirus vaccine called Covaxin from Bharat Biotech, an Indian pharmaceutical business. While it's already approved in India, the chances of Ocugen successfully commercializing Covaxin in the U.S. remain a question mark.
Novavax missed Wall Street expectations but remains optimistic about the fourth quarter and 2023.